{
    "clinical_study": {
        "@rank": "134615", 
        "arm_group": [
            {
                "arm_group_label": "TU-100", 
                "arm_group_type": "Experimental", 
                "description": "15g TU-100 (oral, daily) for 4 consecutive weeks (administered as 5g three times daily)"
            }, 
            {
                "arm_group_label": "Matching placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo given 5g three times daily orally for 4 consecutive weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to assess the effect of orally administered TU-100 (5 g three times\n      daily [TID]) as compared to placebo on abdominal bloating rating in female IBS patients."
        }, 
        "brief_title": "A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Irritable Bowel Syndrome in Females", 
        "condition_browse": {
            "mesh_term": "Irritable Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meet Rome III criteria for IBS (any subtype)\n\n          -  Female aged 18 to 65 years, inclusive\n\n          -  If of childbearing potential, prepared to use suitable forms of contraception\n             throughout the study and for 30 days after the last dose i.e., hormonal\n             contraceptives (such as oral contraceptives, Depo-Provera, NuvaRing, Essure), condoms\n             used with a spermicide, an intrauterine device, or abstinence.  Females are not\n             considered to be of childbearing potential if they are naturally postmenopausal (no\n             menses for at least 1 year and, if < 55 years of age, have a documented\n             follicle-stimulating hormone [FSH] level of \u2265 35 mIU/mL) or have documentation of\n             surgical sterility\n\n          -  Have a BMI between 18 and 30 kg/m2, inclusive\n\n          -  Have a negative pregnancy urine screening at Visit 1, if of childbearing potential\n\n          -  Able to provide written consent\n\n          -  Able to take oral administration of the testing medications\n\n          -  Have a self-reported average abdominal bloating rating (>3 daily ratings over the\n             preceding 7 days) equal or greater than 4 on a numerical scale of 0 to 20.\n\n        Exclusion Criteria:\n\n          -  Have a structural or metabolic disease or condition that affects the GI system,\n             excluding asymptomatic gallstones or uncomplicated gastroesophageal reflux disease,\n             or any medical condition that may be a cause of constipation or diarrhea (e.g.,\n             hypothyroid status, poorly controlled diabetes, diabetic neuropathy or autonomic\n             neuropathy)\n\n          -  Be taking any medication that, in the opinion of the Principle Investigator (PI), has\n             potential to alter GI transit. A full list of prohibited medications is provided in\n             the protocol.  Have history or presence of any chronic lung disease\n\n          -  Have presence of hepatic dysfunction, jaundice, or abnormal serum alanine\n             aminotransferase (ALT) or aspartate aminotransferase (AST) values exceeding 2.5 x\n             upper limit of normal\n\n          -  Currently pregnant or lactating\n\n          -  Have a positive urine drug test at screening (subjects who initially test positive\n             will be allowed one retest)\n\n          -  Be a known substance abuser or be considered to be an alcoholic not in remission\n\n          -  Have participated in another clinical study in the past 30 days\n\n          -  Use of supplemental ginger, ginseng, or Zanthoxylum fruit for 2 weeks prior to\n             randomization and throughout the course of the study.\n\n          -  Have a history of allergic reaction to ginseng, ginger or Zanthoxylum fruit\n\n          -  Be clinically lactose-intolerant\n\n          -  Have any other condition that, in the opinion of the PI, causes the subject to be\n             unsuitable to participate\n\n          -  Have taken antibiotics in the last 3 months\n\n          -  Have had gastroenteritis (\"stomach flu\") in the last 3 months\n\n          -  Have taken probiotics in the last 3 months (over-the-counter [OTC] products or\n             supplements only; food products such as yogurts are permitted)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074579", 
            "org_study_id": "TU100CPT6"
        }, 
        "intervention": [
            {
                "arm_group_label": "TU-100", 
                "description": "15g daily, orally as 5g three times daily for 4 consecutive weeks", 
                "intervention_name": "TU-100", 
                "intervention_type": "Drug", 
                "other_name": "Daikenchuto"
            }, 
            {
                "arm_group_label": "Matching placebo", 
                "description": "Matching placebo given 5g three times daily orally for 4 consecutive weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Irritable Bowel Syndrome", 
            "Rome III criteria", 
            "abdominal bloating", 
            "natural", 
            "herbal", 
            "Kampo", 
            "Adult ages 18 to 65", 
            "Female subjects"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90095"
                }, 
                "name": "Oppenheimer Family Center for Neurobiology of Stress Division of Digestive Diseases David Geffen School of Medicine at UCLA"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Single-center, Randomized, Double-Blinded, Placebo-Controlled Study on the Efficacy of Daikenchuto (TU 100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome", 
        "other_outcome": [
            {
                "description": "Physical examination at Visits 1, 2 and 4", 
                "measure": "Physical Examination", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "2.\tVital signs (pulse, blood pressure, temperature, and respiration rate) at Visits 1, 2 and 4", 
                "measure": "Vital Signs", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Interview for adverse events (AEs) and concomitant medications at Visits 3, 4 and 5", 
                "measure": "Adverse Events and Concomitant Medications", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Laboratory safety tests including hematology, chemistry, and urinalysis at Visits 1, 2 and 4.  Pregnancy test for subjects of childbearing potential at Visits 1, 2, 3, 4 and 5.", 
                "measure": "Laboratory safety tests", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "overall_contact": {
            "email": "jennifer.scott@iconplc.com", 
            "last_name": "Jennifer C Scott, BSN, MS", 
            "phone": "1-215-616-8887"
        }, 
        "overall_official": {
            "affiliation": "Oppenheimer Family Center of Neurobiology of Stress, UCLA", 
            "last_name": "Kirsten Tillisch, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in abdominal bloating rating, through comparison of the change in average ratings from the 7 days prior to baseline (Visit 2) to the last 7 days of the 4 week treatment period (Visit 4), between TU-100 15 g and placebo.", 
            "measure": "Abdominal bloating rating", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in area under the curve (AUC) for abdominal bloating ratings obtained during the lactulose challenge at Visit 2 (baseline) and at Visit 4 (4 weeks). The data are collected at -0.5, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8 hours after taking test meal (lactulose).", 
                "measure": "AUC for abdominal bloating ratings using lactulose challenge", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 4 weeks"
            }, 
            {
                "description": "Change in the average of abdominal bloating ratings from the 7 days prior to baseline to the 7 days prior to Visit 3 (2 weeks) and to Visit 5 (8 weeks)", 
                "measure": "Abdominal bloating ratings", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Change in Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) total score from baseline to Visits 3, 4, and 5", 
                "measure": "Overall IBS Severity", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Change in the average of GI symptom ratings from the 7 days prior to baseline to the 7 days prior to Visit 3 and to Visit 5", 
                "measure": "GI symptom ratings", 
                "safety_issue": "No", 
                "time_frame": "4 week"
            }, 
            {
                "description": "Change in IBS-QOL score from baseline to Visits 3, 4, and 5", 
                "measure": "Quality of Life effect", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Change in the average of mood symptom ratings from the 7 days prior to baseline to the 7 days prior to Visit 3 and to Visit 5", 
                "measure": "Mood symptom ratings", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Tsumura USA", 
        "sponsors": {
            "collaborator": {
                "agency": "ICON Clinical Research", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Tsumura USA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}